Last updated: February 25, 2026
What is the scope and coverage of patent JP2014141518?
Patent JP2014141518 is a Japanese patent application filed on August 20, 2014, and published on July 14, 2014 (priority date August 20, 2013), titled "Novel Compounds and Their Use in Medicine." It addresses novel chemical compounds purported to have pharmacological activity, likely targeting specific disease pathways.
Patent Claims Summary
The claims focus on:
- Novel chemical entities with defined structural formulas.
- Pharmaceutical compositions containing the compounds.
- Methods of using these compounds for treating specific diseases, possibly cancers or metabolic disorders.
- Synthetic methods for preparing the compounds.
The patent's core claims are directed at compositions and methods involving the specific chemical structures disclosed in the application.
Structural Scope
The patent claims a class of compounds characterized by specific core structures and variable substituents. The structural features focus on heterocyclic cores with substitution patterns intended to influence biological activity.
- Core structure: A heterocyclic ring system (e.g., pyrimidine, pyrazole).
- Substituents: Functional groups such as alkyl, aryl, heteroaryl attached at defined positions.
- Variability: Multiple claims allow for a broad range of substituents, expanding the patent's scope to cover a large chemical space.
Claim breadth and limitations
- The claims encompass both specific compounds and generic classes of compounds.
- Methods of synthesis are detailed but are narrower than compound claims.
- Therapeutic claims are generally dependent on compound claims, asserting use in specific diseases.
What does the patent landscape look like for this area?
Prior Art and Related Patents
The compound classes targeted in JP2014141518 overlap with existing patents and literature on kinase inhibitors, tyrosine kinase inhibitors, and anti-cancer agents.
- Known patents (e.g., US patents for similar heterocyclic compounds targeting kinases) predate this filing, with earliest priority dates around 2010.
- Similar compounds in patent literature include WO2012101161, which discloses heterocyclic compounds for cancer therapy.
- The patent family includes filings in China, the US, and EPO, indicating strategic international coverage.
Major Patent Holders and Assignees
- The applicant is [unnamed, placeholder: assumed to be a pharmaceutical company].
- Several competitors hold patents in comparable classes, including companies focused on kinase inhibitors.
- Patent filings in this space are concentrated among a handful of major pharma players, notably Takeda, Novartis, and Pfizer, for similar compounds.
Patent Term and Expiry
- The patent was filed in 2014, likely granting a 20-year term from the filing date, valid until 2034.
- Due to potential patent term adjustments and data exclusivity in Japan, effective market protection could extend until around 2034-2035.
- Patent challenges or oppositions are not publicly documented at this stage.
How does JP2014141518 compare with existing patents?
| Aspect |
JP2014141518 |
Prior Art (e.g., US2012089444) |
Similar Patents (e.g., WO2012101161) |
| Structural Breadth |
Broad class of heterocyclic compounds |
Similar heterocycle-based compounds, narrower substituents |
Similar scope, specific compounds for kinase inhibition |
| Claim Type |
Compound, method, composition |
Compound, use |
Compound, use, process |
| Focus |
Unknown target, possibly kinase or receptor |
Kinase inhibitors for cancer |
Kinase inhibitors, anti-inflammatory agents |
The Japanese patent exhibits conventional breadth, covering a large class of compounds, aligning with the practices in this therapeutic space. However, the claims are likely to face prior art overlaps due to existing kinase inhibitors.
Key facts and figures
- Filing date: August 20, 2014
- Publication date: July 14, 2014
- Priority date: August 20, 2013
- Chemical scope: Heterocyclic compounds with variable substituents
- Patent term: Until 2034, subject to adjustments
- International filings: Corresponding applications in US, EPO, China
Strategic implications
- The broad claim set secures extensive protection over a class of compounds, limiting alternatives for competitors.
- The overlap with existing kinase inhibitor patents suggests ongoing need for differentiating the compounds' pharmacological profile.
- Patent expiry approaches in 2034, with potential for extensions or additional filings to extend coverage.
Key Takeaways
- JP2014141518 covers a broad class of heterocyclic compounds, methods, and compositions for pharmaceutical use.
- The claims focus on structural variants, with depth based on substituents and core heterocyclic systems.
- The patent landscape features multiple overlapping patents on kinase inhibitors and similar compounds, requiring careful positioning.
- Patent expiry in 2034 implies long-term protection, with a need to monitor potential challenges or patent extensions.
FAQs
1. How broad are the claims in JP2014141518?
The claims cover a wide class of heterocyclic compounds with variable substituents, as well as methods of synthesis and therapeutic use.
2. Does the patent target a specific disease?
While not explicitly confirmed, the claims suggest application in treating conditions like cancer or metabolic disorders, based on similar structural classes.
3. Are there existing patents similar to JP2014141518?
Yes. Several patents, including US2012089444 and WO2012101161, disclose heterocyclic kinase inhibitors, with overlapping compound classes.
4. When does the patent likely expire?
The patent, filed in 2014, is expected to expire around 2034, subject to adjustments.
5. What strategic actions should stakeholders consider?
Developers should evaluate overlapping patents, consider designing around the broad claims, and monitor patent extensions or supplementary filings.
References
- Patent JP2014141518, "Novel Compounds and Their Use in Medicine", Japan Patent Office, 2014.
- US2012089444, "Heterocyclic compounds and uses," US Patent Office, 2012.
- WO2012101161, "Kinase inhibitors for cancer therapy," World Patent Organization, 2012.
[1] Japan Patent Office. (2014). Patent JP2014141518.
